ReviewFrontiers in genetics2020
Pharmacogenetics of Statin-Induced Myotoxicity.
Review in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Association Between ABCG2 Polymorphism and Statin-Induced Adverse Events: A Meta-Analysis.Cardiovascular toxicology · 2025Pooled it
- Advances in statin adverse reactions and the potential mechanisms: A systematic review.Journal of advanced research · 2025Pooled it
- Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy.International journal of environmental research and public health · 2022Pooled it
- Factors associated with creatine kinase variability among statin users in routine outpatient care: a retrospective cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- Article
- Association ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Statin Use Is Associated With a Decline in Muscle Function and Mass Over Time, Irrespective of Statin Pharmacogenomic Score.Journal of cachexia, sarcopenia and muscle · 2025Article
- Impact of SLCO1B1 (rs2306283) polymorphism on personalized atorvastatin dosing in a genetically distinct South Asian cohort.BMC pharmacology & toxicology · 2025Article
- Effect of genetic polymorphism of rosuvastatin transporter gene rs2231137 on its clinical efficacy and safety.Scientific reports · 2025Article
- Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.CNS drugs · 2025Review
- Decoding Stroke Etiology: Multi-Omics Advancements in Genetic Mechanisms and Clinical Implication.Brain and behavior · 2025Review
- Exploring the potential of honokiol as a treatment for cardiovascular disease (Review).Biomedical reports · 2025Review
- Determination of the latent geometry of atorvastatin pharmacokinetics by transfer entropy to identify bottlenecks.BMC pharmacology & toxicology · 2025Article
- Increased risk of rhabdomyolysis in patients using statins: a population-based case-control study.Therapeutic advances in drug safety · 2025Article
- Impact ofInternational journal of molecular sciences · 2024Article
- Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.Current vascular pharmacology · 2024Article
- Article
- Cryo-EM structures of human organic anion transporting polypeptide OATP1B1.Cell research · 2023Article
- Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions.Advances in laboratory medicine · 2023Article
- Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins, a class of lipid-lowering medications, have been a keystone treatment in cardiovascular health. However, adverse effects associated with statin use impact patient adherence, leading to statin discontinuation. Statin-induced myotoxicity (SIM) is one of the most common adverse effects, prevalent across all ages, genders, and ethnicities. Although certain demographic cohorts carry a higher risk, the impaired quality of life attributed to SIM is significant. The pathogenesis of SIM remains to be fully elucidated, but it is clear that SIM is multifactorial. These factors include drug-drug interactions, renal or liver dysfunction, and genetics. Genetic-inferred risk for SIM was first reported by a landmark genome-wide association study, which reported a higher risk of SIM with a polymorphism in the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.